Evidence map›Paper›PMID 40858710›Full record

ArticleScientific reports2025

Lysyl oxidase as a potential biomarker of lung recurrence after hepatectomy in hepatocellular carcinoma.

Wan-Ting Xing, Jing-Xuan Xu, Lu-Nan Qi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wan-Ting Xing *Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, No. 71 Hedi Road, Nanning, 530021, Guangxi Province, China.
Jing-Xuan Xu *Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, No. 71 Hedi Road, Nanning, 530021, Guangxi Province, China.
Lu-Nan QiDepartment of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, No. 71 Hedi Road, Nanning, 530021, Guangxi Province, China. qilunan_gxmu@163.com.

Funding

the Innovation Project of Guangxi Graduate Education YCSW2020120the National Nature Science Foundation of China 81972306
6 · The paper itself

Abstract

Lung recurrence following hepatectomy is a common and clinically significant complication in patients with hepatocellular carcinoma (HCC), often leading to poor prognosis. However, the underlying mechanisms and reliable predictive biomarkers remain poorly defined. We performed cDNA microarray analysis to identify genes associated with lung recurrence after hepatectomy in HCC patients and identified lysyl oxidase (LOX) as a candidate. We further evaluated the association between LOX expression, circulating tumor cell (CTC), and microvessel density (MVD). The predictive value of serum LOX levels was assessed in both training and validation cohorts. LOX expression was significantly elevated in HCC patients who developed lung recurrence post-hepatectomy and was associated with worse prognosis. High intratumoral LOX expression correlated with increased CTC counts and elevated MVD. In vitro, LOX overexpression enhanced HCC cell migration and invasion, while LOX knockdown suppressed these phenotypes. Serum LOX levels demonstrated predictive potential for postoperative lung recurrence in both cohorts. LOX overexpression is closely associated with lung recurrence after hepatectomy in HCC patients. LOX may serve as a potential biomarker, and its serum level could be used to predict postoperative lung recurrence.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularHepatectomyLiver NeoplasmsLung NeoplasmsNeoplasm Recurrence, LocalProtein-Lysine 6-OxidaseAgedCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplastic Cells, CirculatingBiomarkers, TumorProtein-Lysine 6-OxidaseCirculating tumor cellHCCLysyl oxidaseMicrovessel densityPostoperative lung recurrence

Identifiers

PMID40858710
PMCPMC12381232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.